drugset / Trial / NCT01266161

Multiple Dose Dental Pain Study Of Ibuprofen Extended Release

NCT01266161 ↗

Phase 3 Completed 106 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

The study hypothesis is that single and multiple doses of ibuprofen 600 mg ER caplets provide analgesic efficacy superior to placebo over 12-hour dosing intervals.

Timeline

Start
2010-11-22
Primary completion
2011-03-31
Completion
2011-03-31

Outcome

Met primary endpoint

registry MEAN Ibuprofen: 41.5 (Standard Deviation 21.0) units on a scale NCT01266161 ↗

registry analysis (superiority test); Placebo vs Ibuprofen; p <0.001; Mean Difference (Final Values) 23.76 (95% CI 16.45 to 31.07); ANOVA NCT01266161 ↗

registry MEAN Ibuprofen: 18.4 (Standard Deviation 12.1) units on a scale NCT01266161 ↗

registry analysis (superiority test); Placebo vs Ibuprofen; p <0.001; Mean Difference (Final Values) 8.42 (95% CI 4.13 to 12.71); ANOVA NCT01266161 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibuprofen Small molecule 600 mg —

Indications

No indication recorded.